NO973103L - Fremgangsmåte for inhibering av veksthormoneffekter - Google Patents

Fremgangsmåte for inhibering av veksthormoneffekter

Info

Publication number
NO973103L
NO973103L NO973103A NO973103A NO973103L NO 973103 L NO973103 L NO 973103L NO 973103 A NO973103 A NO 973103A NO 973103 A NO973103 A NO 973103A NO 973103 L NO973103 L NO 973103L
Authority
NO
Norway
Prior art keywords
growth hormone
inhibiting growth
hormone effects
effects
hexamethylenimino
Prior art date
Application number
NO973103A
Other languages
English (en)
Other versions
NO973103D0 (no
Inventor
Timothy Alan Grese
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO973103L publication Critical patent/NO973103L/no
Publication of NO973103D0 publication Critical patent/NO973103D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Fremgangsmåte for inhibering av veksthormoneffekter Fremgangsmåte for inhibering av effekter av veksthormon omfattende administrasjon til et menneske som har behov for dette av en effektiv mengde av en forbindelse av formel 0) ^;^>Ss^^OCH2CH2-r2 hvor r1 og r3 uavhengig er hydrogen, -CH3, 0 0 -C-(Ci-C6 alkyl) eller -C-Ar, hvor Ar er eventuelt substituert fenyl; r2 er valgt fra gruppen bestående av pyrrolidin, heksametylenimino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO973103A 1995-01-12 1997-07-03 Fremgangsmåte for inhibering av veksthormoneffekter NO973103D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/372,753 US5494929A (en) 1995-01-12 1995-01-12 Methods of inhibiting growth hormone effects
PCT/US1995/016809 WO1996021441A1 (en) 1995-01-12 1995-12-22 Methods of inhibiting growth hormone effects

Publications (2)

Publication Number Publication Date
NO973103L true NO973103L (no) 1997-07-03
NO973103D0 NO973103D0 (no) 1997-07-03

Family

ID=23469503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973103A NO973103D0 (no) 1995-01-12 1997-07-03 Fremgangsmåte for inhibering av veksthormoneffekter

Country Status (12)

Country Link
US (1) US5494929A (no)
EP (1) EP0796095A4 (no)
JP (1) JPH10512260A (no)
KR (1) KR19980701329A (no)
CN (1) CN1177295A (no)
AU (1) AU701267B2 (no)
CA (1) CA2209891A1 (no)
CZ (1) CZ217497A3 (no)
FI (1) FI972968A (no)
HU (1) HUT77381A (no)
NO (1) NO973103D0 (no)
WO (1) WO1996021441A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ES2341399T3 (es) * 1996-03-26 2010-06-18 Eli Lilly And Company Benziotofenos, formulaciones que contienen los mismos y procedimientos.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Also Published As

Publication number Publication date
CN1177295A (zh) 1998-03-25
HUT77381A (hu) 1998-04-28
MX9705215A (es) 1997-10-31
FI972968A0 (fi) 1997-07-11
KR19980701329A (ko) 1998-05-15
AU4659196A (en) 1996-07-31
JPH10512260A (ja) 1998-11-24
WO1996021441A1 (en) 1996-07-18
US5494929A (en) 1996-02-27
CA2209891A1 (en) 1996-07-18
NO973103D0 (no) 1997-07-03
CZ217497A3 (cs) 1998-01-14
FI972968A (fi) 1997-07-11
EP0796095A4 (en) 1999-01-07
AU701267B2 (en) 1999-01-21
EP0796095A1 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
GR3033269T3 (en) Methods of inhibiting viral replication
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944930L (no) Hemming av dysfunksjonell uterin blödning
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft